UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Recruiting
99 years or below
All
Phase
1
28 participants needed
1 Location
Brief description of study
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, ROS1, BRAF, or other driver mutations who receive driver mutation-based therapy in 1st line are excluded from the trial.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Lung Cancer
-
Age: 99 years or below
-
Gender: All
Updated on
24 Sep 2024.
Study ID: 844091
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
